Glenmede Trust Co. NA continued to hold its position in shares of Cytosorbents Corporation (NASDAQ:CTSO) during the first quarter, according to its most recent filing with the SEC. The firm owned 19,008 shares of the medical research company’s stock at the end of the first quarter. Glenmede Trust Co. NA owned 0.07% of Cytosorbents Corporation worth $102,000 as of its most recent SEC filing.
Other institutional investors have also made changes to their positions in the company. Skylands Capital LLC boosted its position in shares of Cytosorbents Corporation by 1,276.5% in the first quarter. Skylands Capital LLC now owns 316,600 shares of the medical research company’s stock valued at $1,425,000 after buying an additional 293,600 shares in the last quarter. Sabby Management LLC acquired a new position in shares of Cytosorbents Corporation during the first quarter valued at about $990,000. Cowen Group Inc. acquired a new position in shares of Cytosorbents Corporation during the first quarter valued at about $248,000. Finally, Segantii Capital Management Ltd boosted its position in shares of Cytosorbents Corporation by 563.4% in the first quarter. Segantii Capital Management Ltd now owns 27,200 shares of the medical research company’s stock valued at $122,000 after buying an additional 23,100 shares in the last quarter. 9.63% of the stock is currently owned by institutional investors.
Shares of Cytosorbents Corporation (NASDAQ CTSO) traded up 1.05% on Wednesday, hitting $4.80. 37,230 shares of the company’s stock traded hands. Cytosorbents Corporation has a 1-year low of $3.30 and a 1-year high of $6.90. The firm’s 50-day moving average price is $4.76 and its 200 day moving average price is $4.83. The company’s market cap is $134.92 million.
Cytosorbents Corporation (NASDAQ:CTSO) last announced its quarterly earnings results on Monday, August 7th. The medical research company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.02. The company had revenue of $3.57 million during the quarter, compared to analysts’ expectations of $3.29 million. Cytosorbents Corporation had a negative return on equity of 529.95% and a negative net margin of 80.56%. On average, equities research analysts expect that Cytosorbents Corporation will post ($0.27) earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://stocknewstimes.com/2017/08/16/glenmede-trust-co-na-has-102000-stake-in-cytosorbents-corporation-ctso-updated-updated-updated.html.
Several equities analysts have recently issued reports on CTSO shares. Maxim Group set a $10.00 price objective on shares of Cytosorbents Corporation and gave the stock a “buy” rating in a research note on Monday, July 17th. B. Riley reaffirmed a “buy” rating and issued a $11.25 price objective on shares of Cytosorbents Corporation in a research note on Wednesday, May 10th. Aegis reiterated a “buy” rating and issued a $9.00 target price on shares of Cytosorbents Corporation in a report on Tuesday, May 9th. Finally, HC Wainwright set a $13.00 target price on shares of Cytosorbents Corporation and gave the stock a “buy” rating in a report on Tuesday, August 8th. Six equities research analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and an average target price of $12.71.
In related news, insider Phillip P. Chan purchased 6,300 shares of the stock in a transaction dated Monday, June 5th. The stock was bought at an average cost of $4.00 per share, with a total value of $25,200.00. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Over the last ninety days, insiders bought 16,500 shares of company stock valued at $66,280. 5.60% of the stock is currently owned by company insiders.
Cytosorbents Corporation Company Profile
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
Receive News & Ratings for Cytosorbents Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
